Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

Abstract: Binding molecules are described.

Abstract: The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same.

Abstract: The present invention provides compounds useful as inhibitors of Btk, compositions thereof, and methods of using the same.

Abstract: Organic Anti-Beta 1 integrin compounds useful for inhibiting cell-adhesion.

Abstract: A compound comprising a Magainin I or Magainin II peptide wherein at least one substitution may be made for certain amino acid residues with other amino acid residues, said peptides known as substitution analogues.In addition to such substitutions, there can be included within the scope of the invention analogues wherein at least one of amino acid residues 15 and 23 may have been deleted as well, and wherein substitutions were made in the remaining peptide chain. Certain substituttion analogues within the scope of the present invention have been shown to possess increased biological activity.

Abstract: A process for the synthesis of a complex mixture pool of solid support-coupled monomeric repeating unit compounds such as amino acid derivatives is disclosed in which the mixture pool contains an equimolar representation of reacted monomeric repeating unit compounds coupled. Also disclosed is a process for the stepwise synthesis of a complex mixture of coupled or free, unsupported oligomers such as oligopeptides. A set of self-solubilizing, unsupported mixed oligopeptides having one or more predetermined amino acid residues at one or more of the same, predetermined positions in the oligopeptide chain in which the set contains equimolar amounts of a plurality of different amino acid residues, preferably at least six different residues, at one or more of the same predetermined positions of the oligopeptide chain is also disclosed, as are methods of making and using the same.

Abstract: A compound comprising a deletion analogue of an amide or carboxy-terminating Magainin I of the following structural formula using the single letter amino acid code: ##STR1## and wherein at least one of amino acid residues 15 through 23 is omitted; or a deletion analogue of an amide or carboxy-terminated Magainin II of the following structural formula using the single letter amino acid code: ##STR2## and wherein at least one of amino acid residues 15 through 23 is omitted. These compounds can be effectively used as pharmaceutical compositions.